Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

6 treatments under study, led by Irinotecan

Research Leaders

6 sponsors active, led by AstraZeneca

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

3Total
Phase 1/2 (1)
Phase 2 (2)

Trial Status

Completed1
Unknown1
Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT06873763Phase 1/2Recruiting

Nelmastobart in Combination With Trifluridine/ Tipiracil and Bevacizumab in Metastatic/ Recurrent Colorectal Cancer

NCT04499586Phase 2UnknownPrimary

A Study of Radiotherapy Combined With Raltitrexed and Irinotecan in Metastatic or Locally Recurrent Colorectal Cancer

NCT01862003Phase 2Completed

Phase I/II Trial of Antagonism of HER in GI Cancer

Showing all 3 trials

Research Network

Common Treatments

  • Irinotecan1
  • Fluorouracil1
  • Leucovorin1
  • Nelmastobart 800 Mgtrifluridinetipiracil Bevacizumab1
  • Radiotherapy Combined With Raltitrexed And Irinotecan1

Active Sponsors

  • AstraZeneca1
  • Fudan University1
  • Cancer Research UK1
  • National Institute for Health Research, United Kingdom1
  • STCube, Inc.1

Top Investigators

Related Conditions

  • Metastatic Colorectal Cancer1
  • Metastatic Colorectal Cancer Crc1

Activity Timeline